Long-term safety and tolerability of REGN727/SAR236553 in High Cardiovascular Risk Patients with Hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, double-blind, placebo-controlled study

Trial Profile

Long-term safety and tolerability of REGN727/SAR236553 in High Cardiovascular Risk Patients with Hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, double-blind, placebo-controlled study

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Registrational
  • Acronyms ODYSSEY-LONG-TERM
  • Sponsors Sanofi
  • Most Recent Events

    • 15 Nov 2017 Results of pooled analysis from ten ODYSSEY trials assessing characteristics of patients with less than 5% LDL-C reduction presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 15 Nov 2017 Results of post-hoc analysis of 3 phase III ODYSSEY trials (COMBO I, COMBO II and LONG TERM) presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 15 Nov 2017 Results of post-hoc analysis examined impact of age on efficacy and safety of ALI in patients with HeFH, using pooled data from four 78-week ODYSSEY Phase 3 trials (FH I,FH II ,HIGH FH and LONG TERM), were presented at the 90th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top